ALLIANCE Webinar on Assessing impact of production, use and disposal of radiopharmaceuticals on members of public and the environment

The ALLIANCE organised the webinar the 2^nd of June, 2022. The webinar aimed at gathering information, including insight experiences from regulators, scientists, producers of radiopharmaceuticals (RPs) and experts in the field of nuclear medicine, necessary to carry out dose assessments for members of the public and non-human-biota. About 60 people (scientists working at universities and research centres for nuclear medicine, hospitals as well as in regulatory bodies) attended the webinar from all over the world.

AGENDA

9:30 – 9:45 Welcome and Introduction on behalf of ALLIANCE. Laura Urso (BfS, Germany)

Session 1: Overview of the use of medical radionuclides in Europe and future perspective.

09:45 – 10:15    Sustainable and Resilient supply of Medical Radioisotopes in the EU: current and future use, trends and challenges. Chiel Scholten (Technopolis Group, Netherlands).

10:15 – 10:30    Questions and discussion on Session 1.

Session 2: Regulatory framework and national approaches 

10:30 – 11:00    Nuclear Medicine in Finland – Regulatory Control and Current Challenges.  Sampsa Kaijaluoto (STUK, Finland).

11:00 – 11:20    Regulatory challenges in the monitoring of medical radioactive effluents. Geert Biermans (FANC, Belgium).

11:25 – 11:55    Regulatory Control and Current Challenges of use of medical radioisotopes in Italy.  Cinzia Pettinato (Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Italy).

11:55 – 12:10    Questions and Discussion on Session 2.

Session 3: Radionuclides production, radiopharmaceuticals manufacturing, medical application, environmental fate including clearance or final disposal of related nuclear waste.

12:40 – 13:10    Application of medical RNs for outpatient treatment: possible impact on members of the public. Philipp Hartmann (BfS, Germany).

13:10 – 13:40    Ac-225, Ge-68 und Lu-177 – Radioisotopes for diagnostics and therapy. Marian Meckel (ITM Medical Isotopes GmbH, Germany).

13:40 – 14:10    Significant I-131 releases from the radiopharmaceutical industry under normal operating and incident conditions. Olivier Masson (IRSN, France).

14:10 – 14:50    Assessment of the radiological impact on the public of radionuclide discharges in sewage systems. Eric Blanchardon (IRSN, France).

15:00 – 15:30    Waste management at the fission Mo-99 processors, with a drive to limit the environmental impact. Veerle Van de Steen (IRE, Belgium).

15:30 – 15:45    Questions and discussion on Session 3.

Session 4: Identifying data gaps for exposure assessments

15:45 – 16:15 Identification of data gaps for medical RNs for the calculation of doses to human and non-human biota. Jordi Vives i Batlle (SCK CEN, Belgium).

16:15 – 16:30    Conclusive remarks

« Return to previous page